10:23 a.m. ET -- Roche Holding AG is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Roche said its experimental Alzheimer's drug failed to significantly slow cognitive decline in long-awaited trials, the latest in a long line of setbacks for a field that has seen little progress in decades. The drug, called gantenerumab, slightly reduced cognitive decline in people with early Alzheimer's compared with a placebo across two large and lengthy trials, but the difference wasn't statistically significant, Roche said Monday. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)


(END) Dow Jones Newswires

11-14-22 1038ET